Secondary Offering for Immuron Limited
Immuron is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies that Immuron believes can address significant unmet medical needs. Immunomodulator polyclonol antibodies are blood proteins that are produced by the immune system to attack foreign substances such as bacteria and can be specifically utilized to increase and/or decrease the activity of the immune system. Immuron's oral polyclonal antibodies offer targeted delivery within the gastrointestinal (GI) track but do not cross into the bloodstream. Immuron believes that its two lead immunomodulator product candidates, IMM-124E and IMM-529, have the potential to transform the existing treatment paradigms for NASH (Non Alcoholic Steatohepatitis) and for Clostridium difficile (C. difficile), respectively. Immuron also markets an OTC product, Travelan, has been designated by the Therapeutic Goods Administration ("TGA") in Australia and Health Canada as being preventative to Traveler's Diarrhea . Travelan is also based on the same technology.Show More
Secondary Offering Documentation
Key Secondary Offering Data
How Does a Secondary Offering Work?
Open a Motif Account
Open a brokerage account to get ready for trading.
Participate in an Offering
Review secondary offering pricing, prospectus, and other documentation.
Place a Conditional Order
Select an investment amount and fund the secondary offering.